Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT

M. Nabergoj, K. Mauff, M. Robin, N. Kröger, E. Angelucci, X. Poiré, J. Passweg, A. Radujkovic, U. Platzbecker, S. Robinson, A. Rambaldi, SL. Petersen, F. Stölzel, M. Stelljes, F. Ciceri, J. Mayer, M. Ladetto, LC. de Wreede, L. Koster, PJ. Hayden,...

. 2021 ; 56 (8) : 1944-1952. [pub] 20210406

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003977
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 1997-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 33824436
DOI 10.1038/s41409-021-01271-4
Knihovny.cz E-zdroje

Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51-63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003977
003      
CZ-PrNML
005      
20240516121434.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-021-01271-4 $2 doi
035    __
$a (PubMed)33824436
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Nabergoj, Mitja $u Division of Hematology, Hôpitaux Universitaires De Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland. mitja.nabergoj@gmail.com
245    10
$a Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT / $c M. Nabergoj, K. Mauff, M. Robin, N. Kröger, E. Angelucci, X. Poiré, J. Passweg, A. Radujkovic, U. Platzbecker, S. Robinson, A. Rambaldi, SL. Petersen, F. Stölzel, M. Stelljes, F. Ciceri, J. Mayer, M. Ladetto, LC. de Wreede, L. Koster, PJ. Hayden, T. Czerw, JC. Hernández-Boluda, D. McLornan, Y. Chalandon, I. Yakoub-Agha
520    9_
$a Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51-63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.
650    12
$a nemoc štěpu proti hostiteli $7 D006086
650    12
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    12
$a nádory $7 D009369
650    12
$a primární myelofibróza $x terapie $7 D055728
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a příprava pacienta k transplantaci $7 D019172
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mauff, Katya $u EBMT Statistical Unit Date Office, Leiden, the Netherlands
700    1_
$a Robin, Marie $u Hôpital Saint-Louis, APHP, Université Paris 7, Paris, France
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany
700    1_
$a Angelucci, Emanuele $u Ematologia e Centro Trapianti, IRCCS Ospedale Policlinico San Martino, Genova, Italy
700    1_
$a Poiré, Xavier $u Cliniques Universitaires St. Luc, Brussels, Belgium
700    1_
$a Passweg, Jakob $u University Hospital, Basel, Switzerland
700    1_
$a Radujkovic, Aleksandar $u University of Heidelberg, Heidelberg, Germany
700    1_
$a Platzbecker, Uwe $u Department of Hematology and Cellular Therapy, University Hospital of Leipzig, Leipzig, Germany
700    1_
$a Robinson, Stephen $u Bristol Royal Hospital for Children, Bristol, UK
700    1_
$a Rambaldi, Alessandro $u University of Milan and Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy $7 xx0317376
700    1_
$a Petersen, Søren Lykke $u Bone Marrow Transplant Unit, Copenhagen, Denmark
700    1_
$a Stölzel, Fridrich $u Universitaetsklinikum Dresden, Dresden, Germany
700    1_
$a Stelljes, Matthias $u University of Muenster, Muenster, Germany
700    1_
$a Ciceri, Fabio $u Ospedale San Raffaele, Milano, Italy
700    1_
$a Mayer, Jiri $u University Hospital Brno, Brno, Czech Republic
700    1_
$a Ladetto, Marco $u H SS. Antonio e Biagio, Alessandria, Italy
700    1_
$a de Wreede, Liesebeth C $u Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands
700    1_
$a Koster, Linda $u EBMT Data Office, Leiden, the Netherlands
700    1_
$a Hayden, Patrick J $u Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland
700    1_
$a Czerw, Tomasz $u Maria Skłodowska-Curie Institute - Cancer Center, Gliwice Branch, Gliwice, Poland
700    1_
$a Hernández-Boluda, Juan Carlos $u Department of Hematology, Hospital Clínico Universitario, Valencia, Spain
700    1_
$a McLornan, Donal $u Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK
700    1_
$a Chalandon, Yves $u Division of Hematology, Hôpitaux Universitaires De Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, univ Lille, INSERM U1286, INFINITE, 59000, Lille, France. ibrahim.yakoubagha@chru-lille.fr
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 56, č. 8 (2021), s. 1944-1952
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33824436 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20240516121428 $b ABA008
999    __
$a ok $b bmc $g 1751437 $s 1155126
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 56 $c 8 $d 1944-1952 $e 20210406 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace